Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "efruxifermin"


3 mentions found


Palantir Technologies — Shares of the data analytics company added 2.3% on news that the U.S. Army awarded the company a $250 million contract to test and develop artificial intelligence and machine learning. Unity Software — The game engine stock surged nearly 6% after the company said CEO John Riccitiello would retire. Rivian Automotive — Shares of the electric truck company rose 3% in premarket trading after UBS upgraded Rivian to buy from neutral. PepsiCo — Shares of the beverage giant added roughly 1% after a third-quarter earnings beat. Akero Therapeutics — The biotech company plummeted more than 63% after reporting initial trial data related to a Phase 2B study of cirrhosis drug efruxifermin.
Persons: John Riccitiello, James M, Whitehurst, Rivian, Davidson, Goldman Sachs, , Jesse Pound, Sarah Min Organizations: U.S . Army, Software, UBS, PepsiCo —, LSEG, Ameris, Bancorp, Arm Holdings, JPMorgan, Deutsche Bank, Akero Therapeutics
Solar companies — Shares of solar companies rallied Tuesday, putting the Invesco Solar ETF (TAN) on pace for its best day since March 21. The defense and aerospace companies rose Monday after the Israel-Hamas war began over the weekend. Rivian — Shares of the electric vehicle manufacturer rose more than 5% after UBS upgraded the stock to buy from neutral. Block — Shares added 5.5% after Bank of America reiterated its buy rating on the payments stock. Unity Software — The video game software company added 3.2%.
Persons: Skechers, SolarEdge, Hannon Armstrong, Baird, Rivian, Joseph Spak, Semafor, Jason Kupferberg, efruxifermin, John Riccitiello, James Whitehurst, Davidson, — CNBC's Pia Singh, Tanaya Macheel, Jesse Pound, Michelle Fox, Lisa Kailai Han, Samantha Subin Organizations: UBS, Palantir Technologies, U.S . Army, PepsiCo, LSEG, Sustainability, Bank of America, Electronic Arts, EA's FIFA, Technologies, Northrop Grumman, Hamas, Truist, Therapeutics, Unity Software, Unity, Arm, Deutsche Bank, JPMorgan, Arm Holdings Locations: Israel
Akero Therapeutics could be a winner in the race to treat non-alcoholic steatohepatitis, a potentially life-threatening liver disease. Nash is a severe form of fatty liver disease which can cause inflammation of the liver and fibrosis, or scarring, of the liver. The disease can also lead to cirrhosis, in which the liver is permanently damaged. Individuals with Nash are part of the 20% of adults in the U.S. who have NAFLD, or non-alcoholic fatty liver disease. AKRO YTD mountain Akero Therapeutics stock.
Persons: steatohepatitis, Eliana Merle, Akero, Nash, NASH, Merle, NASH cirrhotics, — CNBC's Michael Bloom Organizations: U.S . Food, Drug Administration, Therapeutics Locations: U.S, Nash
Total: 3